Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis

BMC Medicine

Jie Qiao¹  Xue Zhang¹  Bin-Bin Tu²  Ping Liu²  Ying Wang¹  Chun-Mei Zhang¹  Na-Na Liu¹  Yan Yang²  Li-Na Wang²  Rong Li¹  Li Fu¹  Yue Zhao¹ 

[1] Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, China;Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing, China

关键词: inflammation;    insulin resistance;    carbohydrate and lipid metabolism;    amino acid metabolism;    polycystic ovary syndrome;   

Others  :  857272
DOI  :  10.1186/1741-7015-10-153

 received in 2012-06-26, accepted in 2012-11-30,  发布年份 2012

【 摘 要 】

Background

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder accompanied with an increased risk of developing type 2 diabetes mellitus and cardiovascular disease; despite being a common condition, the pathogenesis of PCOS remains unclear. Our aim was to investigate the potential metabolic profiles for different phenotypes of PCOS, as well as for the early prognosis of complications.

Methods

A total of 217 women with PCOS and 48 healthy women as normal controls were studied. Plasma samples of subjects were tested using two different analytical platforms of metabolomics: ¹H nuclear magnetic resonance (NMR) and gas chromatography/time-of-flight mass spectrometry (GC/TOF-MS).

Results

Our results showed that carbohydrate, lipid and amino acid metabolisms were influenced in PCOS. The levels of lactate, long-chain fatty acids, triglyceride and very low-density lipoprotein were elevated, while glucose, phosphatidylcholine and high-density lipoprotein (HDL) concentrations were reduced in PCOS patients as compared with controls. Additionally, the levels of alanine, valine, serine, threonine, ornithine, phenylalanine, tyrosine and tryptophan were generally increased, whereas the levels of glycine and proline were significantly reduced in PCOS samples compared to controls. Furthermore, the ratio of branched-chain amino acid to aromatic amino acid concentrations (BCAA/AAA) in PCOS plasma was significantly reduced in PCOS patients and was insusceptible to obesity and insulin sensitivity.

Conclusions

Our results suggested that the enhanced glycolysis and inhibited tricarboxylic acid cycle (TAC) in women with PCOS. Decrease of BCAA/AAA ratio was directly correlated with the development of PCOS. Ovulatory dysfunction of PCOS patients was associated with raised production of serine, threonine, phenylalanine, tyrosine and ornithine. Elevated levels of valine and leucine, and decreased concentrations of glycine in PCOS plasma could contribute to insulin sensitivity and could be considered as the potential biomarkers for long-term risk assessment of diabetes mellitus.

【 授权许可】

   
2012 Zhao et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R: Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol 2011, 7:219-231.
• [2]Norman RJ, Dewailly D, Legro RS, Hickey TE: Polycystic ovary syndrome. Lancet 2007, 370:685-697.
• [3]Rizzo M, Berneis K, Spinas G, Rini GB, Carmina E: Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertil Steril 2009, 91:1563-1567.
• [4]Moran LJ, Misso ML, Wild RA, Norman RJ: Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010, 16:347-363.
• [5]Hughes C, Elgasim M, Layfield R, Atiomo W: Genomic and post-genomic approaches to polycystic ovary syndrome--progress so far: Mini Review. Hum Reprod 2006, 21:2766-2775.
• [6]Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou G, Papanastasiou L, Bergiele A, Panidis D: Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) 2006, 5:17-34.
• [7]Diamanti-Kandarakis E: Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Exp Rev Mol Med 2008, 10:e3.
• [8]Mukherjee S, Maitra A: Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 2010, 131:743-760.
• [9]Azziz R: Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab 2002, 87:4085-4087.
• [10]Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C: Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown) 2008, 9:987-992.
• [11]Wang ET, Calderon-Margalit R, Cedars MI, Daviglus ML, Merkin SS, Schreiner PJ, Sternfeld B, Wellons M, Schwartz SM, Lewis CE, Williams OD, Siscovick DS, Bibbins-Domingo K: Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol 2011, 117:6-13.
• [12]Franks S: Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006, 91:786-789.
• [13]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
• [14]Wishart DS: Metabolomics: the principles and potential applications to transplantation. Am J Transplant 2005, 5:2814-2820.
• [15]Lenz EM, Wilson ID: Analytical strategies in metabonomics. J Proteome Res 2007, 6:443-458.
• [16]Wu Q, Zhang Q, Sun B, Yan X, Tang Y, Qiao X, Chen Q, Yu S, Liang F: 1H NMR-based metabonomic study on the metabolic changes in the plasma of patients with functional dyspepsia and the effect of acupuncture. J Pharm Biomed Anal 2010, 51:698-704.
• [17]Feng B, Wu S, Lv S, Liu F, Chen H, Yan X, Li Y, Dong F, Wei L: Metabolic profiling analysis of a d-galactosamine/lipopolysaccharide-induced mouse model of fulminant hepatic failure. J Proteome Res 2007, 6:2161-2167.
• [18]Yang Y, Qiao J, Li R, Li MZ: Is interleukin-18 associated with polycystic ovary syndrome? Reprod Biol Endocrinol 2011, 9:7. BioMed Central Full Text
• [19]Sun L, Hu W, Liu Q, Hao Q, Mao S, Sun B, Zhang Q, Qiao J, Yan X: Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res 2012, 11:2937-2946.
• [20]Wild RA, Rizzo M, Clifton S, Carmina E: Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011, 95:1073-1079.
• [21]Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N: Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001, 54:447-453.
• [22]Marei WF, Wathes DC, Fouladi-Nashta AA: Impact of linoleic acid on bovine oocyte maturation and embryo development. Reproduction 2010, 139:979-988.
• [23]Toborek M, Lee YW, Garrido R, Kaiser S, Hennig B: Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. Am J Clin Nutr 2002, 75:119-125.
• [24]Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WJ, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP: A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009, 9:311-326.
• [25]Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Flore JC, Souza A, Melander O, Clish CB, Gerszten RE: Metabolite profiles and the risk of developing diabetes. Nat Med 2011, 17:448-453.
• [26]Wurtz P, Tiainen M, Makinen VP, Kangas AJ, Soininen P, Saltevo J, Keinanen-Kiukaanniemi S, Mantyselka P, Lehtimaki T, Laakso M, Jula A, Kahonen M, Vanhala M, Ala-Korpela M: Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care 2012, 35:1749-1756.
• [27]Garcia-Macedo R, Sanchez-Munoz F, Almanza-Perez JC, Duran-Reyes G, Alarcon-Aguilar F, Cruz M: Glycine increases mRNA adiponectin and diminishes pro-inflammatory adipokines expression in 3T3-L1 cells. Eur J Pharmacol 2008, 587:317-321.
• [28]Toulis KA, Goulis DG, Farmakiotis D, Georgopoulos NA, Katsikis I, Tarlatzis BC, Papadimas I, Panidis D: Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009, 15:297-307.
• [29]Li F, Yin Y, Tan B, Kong X, Wu G: Leucine nutrition in animals and humans: mTOR signaling and beyond. Amino Acids 2011, 41:1185-1193.
• [30]Macotela Y, Emanuelli B, Bang AM, Espinoza DO, Boucher J, Beebe K, Gall W, Kahn CR: Dietary leucine--an environmental modifier of insulin resistance acting on multiple levels of metabolism. PLoS One 2011, 6:e21187.
• [31]Chand AL, Legge M: Amino acid transport system L activity in developing mouse ovarian follicles. Hum Reprod 2011, 26:3102-3108.
• [32]Guastella E, Longo RA, Carmina E: Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010, 94:2197-2201.
• [33]Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I, Macut D: Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2012, 27:541-549.
• [34]Carmina E, Guastella E, Longo RA, Rini GB, Lobo RA: Correlates of increased lean muscle mass in women with polycystic ovary syndrome. Eur J Endocrinol 2009, 161:583-589.
• [35]Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramirez M, Lasuncion MA, Correig X: Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem 2012, 58:999-1009.
• [36]Chen MJ, Chiu HM, Chen CL, Yang WS, Yang YS, Ho HN: Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2010, 95:3332-3341.
• [37]Diao FY, Xu M, Hu Y, Li J, Xu Z, Lin M, Wang L, Zhou Y, Zhou Z, Liu J, Sha J: The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray. J Mol Endocrinol 2004, 33:59-72.